Physicians' Academy for Cardiovascular Education

SGLT2i

Benefits and evolving insights on SGLT2i in the spectrum of LVEF

10' education - June 29, 2022 - Prof. Carolyn Lam, MD, PhD

Management of high risk patients with HFrEF

10' education - June 28, 2022 - Prof. Javed Butler, MD and Shelley Zieroth, MD

The clinical challenges of initiating guideline recommended therapy in HF

10' education - June 21, 2022 - Prof. John McMurray, MD

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events

3' education - Aug. 29, 2021 - Prof. Stefan Anker, MD, PhD

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD

Kidney and HF outcomes with SGLT2i across EF spectrum in HF

3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD

Exciting findings of a pooled analysis of two large HF trials with SGLT2i

3' education - Aug. 27, 2021 - Milton Packer, MD

Another chapter in the SGLT2i book

3' education - Aug. 27, 2021 - Prof. Rudolf de Boer, MD, PhD

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

Benefits and evolving insights on SGLT2i in the spectrum of LVEF

10' education - June 29, 2022 - Prof. Carolyn Lam, MD, PhD
Prof. Lam talks about effects of SGLT2i in HF across the spectrum of LVEF and reviews current guideline treatment recommendations.

Prof. Lam talks about effects of SGLT2i in HF across the spectrum of LVEF and reviews current guideline treatment recommendations.

Management of high risk patients with HFrEF

10' education - June 28, 2022 - Prof. Javed Butler, MD and Shelley Zieroth, MD
Javed Butler and Shelley Zieroth talk about the effects and tolerability of SGLT2i and the oral soluble guanylate cyclase stimulator vericiguat in patients with HFrEF.

Javed Butler and Shelley Zieroth talk about the effects and tolerability of SGLT2i and the oral soluble guanylate cyclase stimulator vericiguat in patients with HFrEF.

Updates to the Standards of Medical Care in Diabetes 2022 by ADA

News - June 21, 2022

The American Diabetes Association (ADA) has made important updates to the Standard of Medical Care in Diabetes 2022. Updates include new data on finerenone in T2DM and CKD, SGLT2i in T2DM and calculating eGFR.

The clinical challenges of initiating guideline recommended therapy in HF

10' education - June 21, 2022 - Prof. John McMurray, MD
Prof. McMurray talks about barriers and concerns regarding Prof. McMurray talks about barriers and concerns regarding initiating guideline recommended therapy in patients with heart failure.

Prof. McMurray talks about barriers and concerns regarding initiating guideline recommended therapy in patients with heart failure.

SGLT2i reduces incidence of hyperkalemia in HF patients

Literature - June 21, 2022 - Ferreira JP, et al. - Eur Heart J. 2022

Hyperkalemia frequently leads to the interruption or discontinuation of treatment with RAAS inhibitors, which may worsen the prognosis of patients with HF. The SGLT2 inhibitor empagliflozin may offer relief here.

Pooled analysis shows no new safety concerns of SGLT2i in T2DM patients with CKD

Literature - June 8, 2022 - Tuttle KR, et al. - Diabetes Care. 2022

By pooling data from 20 RCTs, researchers analyzed the adverse event rate with empagliflozin versus placebo in 2367 T2DM patients with moderate to severe CKD.

Cardiologists account for small proportion of all use of SGLT2is and GLP-1RAs

Literature - May 31, 2022 - Adhikari R, et al. - J Am Heart Assoc. 2022

Although American cardiologists are increasingly prescribing SGLT2is and GLP‐1RAs since 2015, they accounted for <2% of all use in 2020. This could contribute to the known undertreatment of T2DM patients with high CVD risk.

Decongestive effects of SGLT2i in acute HF

News - May 25, 2022

ESC Heart Failure 2022 An analysis of the EMPULSE trial investigated the decongestive effects of empagliflozin compared with placebo in addition to standard medical treatment.

Effects of SGLT2i on peak VO2 in patients with HFrEF

News - May 25, 2022

ESC Heart Failure 2022 A randomized clinical trial investigated the effect of dapagliflozin on maximal functional capacity at 1 and 3 months in patients with stable HFrEF.

SGLT2i improves symptoms in HF across the range of LVEF

News - May 23, 2022
**ESC Heart Failure 2022** A pooled patient-level analysis of DEFINE-HF and PRESERVED-HF investigated the effect of dapagliflozin on symptoms and physical limitations across the range of LVEF.

ESC Heart Failure 2022 A pooled patient-level analysis of DEFINE-HF and PRESERVED-HF investigated the effect of dapagliflozin on symptoms and physical limitations across the range of LVEF.

Primary endpoint met in phase III trial with SGLT2i in HFpEF

News - May 9, 2022

A significant reduction in the primary composite endpoint of CV death or worsening HF was reached with dapagliflozin in HF patients with LVEF >40% in the DELIVER phase III trial.

Influence of MRA use on benefit of SGLT2i in HFpEF

Literature - Apr. 28, 2022 - Ferreira JP, et al. - J Am Coll Cardiol. 2022

A secondary analysis of the EMPEROR-Preserved shows that empagliflozin reduces the primary outcome regardless of background mineralocorticoid receptor antagonists (MRA) therapy. Reduction of total HF hospitalization was more pronounced in MRA nonusers.